Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis

Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis

Background: Natalizumab (NAT) is a high-efficacy treatment for relapsing remitting multiple sclerosis (RRMS). However, it is associated with an increased risk of progressive multifocal leukoencephalopathy that sometimes requires treatment cessation with a risk of returning disease activity. The aim...

Full description

Bibliographic Details
Main Authors:	Undine Proschmann, Hernan Inojosa, Katja Akgün, Tjalf Ziemssen
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-04-01
Series:	Frontiers in Neurology
Subjects:	multiple sclerosis natalizumab (TYSABRI) natalizumab concentration neurofilament light (NFL) chain recurrence of disease activity cessation of natalizumab
Online Access:	https://www.frontiersin.org/articles/10.3389/fneur.2021.650530/full

Similar Items

Drug and Neurofilament Levels in Serum and Breastmilk of Women With Multiple Sclerosis Exposed to Natalizumab During Pregnancy and Lactation
by: Undine Proschmann, et al.
Published: (2021-08-01)

A Systematic Review and Meta-analysis on Safety and Effectiveness of Extended-interval Dosing of Natalizumab in Patients with Relapsing-remitting Multiple Sclerosis: Is There Any Value in The Cost of Treatment? (PP-08)
by: Taraneh Mousavi, et al.
Published: (2023-01-01)

Real-World Lab Data in Natalizumab Treated Multiple Sclerosis Patients Up to 6 Years Long-Term Follow Up
by: Maxi Kaufmann, et al.
Published: (2018-12-01)

Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis
by: Mehdi Rezaee, et al.
Published: (2022-01-01)

Eosinophilic Pneumonia Associated With Natalizumab In A Patient With Multiple Sclerosis: A Case Report And Literature Review
by: Yasuda Y, et al.
Published: (2019-11-01)

The effect of natalizumab on disability score and relapse rate of multiple sclerosis patients: a prospective cohort study
by: Mehrdokht Mazdeh, et al.
Published: (2018-11-01)

Pulmonary eosinophilia associated to treatment with natalizumab
by: Elena Curto, et al.
Published: (2016-01-01)

Patient monitoring during treatment with natalizumab (ORP-24)
by: Zohreh Abna
Published: (2023-01-01)

Natalizumab-Induced Pustular Psoriasis of Palms and Soles
by: Bengisu Ozarslan, et al.
Published: (2022-05-01)

The Age-Related Efficacy of Dimethyl Fumarate and Natalizumab in the Real-World Management of Multiple Sclerosis
by: Roberto De Masi, et al.
Published: (2021-01-01)

Brain atrophy patterns in multiple sclerosis patients treated with natalizumab and its clinical correlates
by: Arwa Rekik, et al.
Published: (2022-05-01)

Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION―A 2-Year, Multicenter, Observational, Cohort Study
by: Helmut Butzkueven, et al.
Published: (2022-02-01)

The use of natalizumab for multiple sclerosis
by: Brandstadter R, et al.
Published: (2017-06-01)

JC virus detection and JC virus-specific immunity in natalizumab-treated Multiple Sclerosis patients
by: Mancuso Roberta, et al.
Published: (2012-12-01)

Alterations of the miR-126-3p/POU2AF1/Spi-B Axis and JCPyV Reactivation in Multiple Sclerosis Patients Receiving Natalizumab
by: Roberta Mancuso, et al.
Published: (2022-03-01)

Altered expression of microRNAs and B lymphocytes during Natalizumab therapy in multiple sclerosis
by: André Eduardo de Almeida Franzoi, et al.
Published: (2021-06-01)

Natalizumab in patients with multiple sclerosis in Colombia: a case series
by: Juan Raúl García Bonitto, et al.
Published: (2020-06-01)

Clinical Immunological Correlations in Patients with Multiple Sclerosis Treated with Natalizumab
by: Smaranda Maier, et al.
Published: (2020-10-01)

Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab
by: Roberta Antonia Diotti, et al.
Published: (2016-05-01)

Interferon-beta increases plasma ceramides of specific chain length in multiple sclerosis patients, unlike fingolimod or natalizumab
by: Florian Ottenlinger, et al.
Published: (2016-11-01)

Anxiety and Perception of Disease Control in Multiple Sclerosis Subjects Treated with Natalizumab
by: Francesco Corallo, et al.
Published: (2023-12-01)

Rapid Progression of Low-Grade Cervical Dysplasia into Invasive Cancer during Natalizumab Treatment for Relapsing Remitting Multiple Sclerosis
by: King Man Wan, et al.
Published: (2019-01-01)

Evaluation of Natalizumab Pharmacokinetics and Pharmacodynamics: Toward Individualized Doses
by: Jose M. Serra López-Matencio, et al.
Published: (2021-10-01)

Presymptomatic diagnosis with MRI and adequate treatment ameliorate the outcome after natalizumab-associated progressive multifocal leukoencephalopathy (PML).
by: Hans eLindå, et al.
Published: (2013-02-01)

Piloting home infusions of Tysabri (natalizumab): a randomised crossover trial
by: Tim Schultz, et al.
Published: (2019-08-01)

Natalizumab Induces Changes of Cerebrospinal Fluid Measures in Multiple Sclerosis
by: Ranjani Ganapathy Subramanian, et al.
Published: (2021-11-01)

Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia
by: Mansour A. Alharbi, et al.
Published: (2023-05-01)

Thinking Outside the Ischemia Box: Advancements in the Use of Multiple Sclerosis Drugs in Ischemic Stroke
by: Athina-Maria Aloizou, et al.
Published: (2021-02-01)

Natalizumab Treatment of Relapsing Remitting Multiple Sclerosis Has No Long-Term Effects on the Proportion of Circulating Regulatory T Cells
by: Radu Tanasescu, et al.
Published: (2023-09-01)

Natalizumab promotes activation and pro-inflammatory differentiation of peripheral B cells in multiple sclerosis patients
by: Jan W. Traub, et al.
Published: (2019-11-01)

Evolução favorável de recidiva de infecção por varicela zoster (cobreiro) durante uso de natalizumabe em paciente com esclerose múltipla: relato de caso
by: Diego Rafhael Soares Carvalho Feitosa, et al.
Published: (2017-04-01)

Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis
by: Yara Dadalti Fragoso, et al.
Published: (2016-08-01)

Effectiveness of Natalizumab in Achieving No Evidence of Disease Activity (NEDA-3)—Data From a Local Norwegian Cohort
by: Andreas K. Jaklin, et al.
Published: (2021-10-01)

Sequence analysis of the non-coding control region of John Cunningham virus isolates from patients with multiple sclerosis treated with natalizumab
by: Marina A. Tyumentseva, et al.
Published: (2023-04-01)

Health care resource utilization before and after natalizumab initiation among patients with multiple sclerosis in Germany
by: Watson C, et al.
Published: (2017-02-01)

Real-World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort
by: Juliette Pelle, et al.
Published: (2023-02-01)

Does Natalizumab Induce or Aggravate Psoriasis? A Case Study and Review of the Literature
by: Sakis Lambrianides, et al.
Published: (2018-09-01)

Progression of a series of patients with relapsing-remitting multiple sclerosis treated for 7 years with natalizumab using the “no evidence of disease activity” parameter
by: A. Pato Pato, et al.
Published: (2021-06-01)

Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring
by: Kathy Khoy, et al.
Published: (2020-09-01)

Multiple Sclerosis Treatment and Melanoma Development
by: Maria Luigia Carbone, et al.
Published: (2020-04-01)